ER-POSITIVE HER2-NEGATIVE BREAST CANCER
Clinical trials for ER-POSITIVE HER2-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER-POSITIVE HER2-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ER-POSITIVE HER2-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill combo aims to delay chemo in advanced breast cancer
Disease control Recruiting nowThis phase 3 trial is testing two oral drugs, camizestrant and ribociclib, as a first treatment for people with ER-positive, HER2-negative advanced breast cancer. The goal is to see if the combination can delay the need for next cancer therapy. About 150 participants will take th…
Matched conditions: ER-POSITIVE HER2-NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Blood test catches cancer early: new drug aims to stop spread
Disease control Recruiting nowThis Phase 3 trial tests whether elacestrant, a new hormone therapy, can prevent distant metastasis better than standard hormone therapies in 220 patients with ER+/HER2- breast cancer whose blood tests show signs of cancer DNA (ctDNA) but no visible spread. Participants are rando…
Matched conditions: ER-POSITIVE HER2-NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a smart drug cross the Blood-Brain barrier to attack breast cancer metastases?
Disease control Recruiting nowThis phase 2 trial is testing whether the investigational drug datopotamab deruxtecan (Dato-DXd) can safely and effectively treat HER2-negative breast cancer that has spread to the brain. The study enrolls adults with metastatic breast cancer who have brain metastases that are ei…
Matched conditions: ER-POSITIVE HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Nancy Lin, MD • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for advanced breast cancer: experimental drug targets resistant tumors
Disease control Recruiting nowThis early-stage trial tests a new drug, GDC-0587, alone or with another drug (giredestrant), in people with advanced ER-positive, HER2-negative breast cancer whose cancer worsened after prior CDK4/6 inhibitor therapy. The study aims to find safe doses and check for side effects.…
Matched conditions: ER-POSITIVE HER2-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New hope for advanced breast cancer: umbrella trial tests multiple drug cocktails
Disease control Recruiting nowThis study is testing several different drug combinations in people with advanced ER-positive breast cancer that has stopped responding to prior treatments. The trial is designed like an 'umbrella,' allowing new drug combos to be added as they become available. About 316 particip…
Matched conditions: ER-POSITIVE HER2-NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a chemo pill mop up hidden breast cancer cells?
Disease control Recruiting nowThis phase 2 trial tests whether the chemotherapy pill capecitabine can eliminate tiny amounts of cancer DNA still present in the blood after standard treatment for early-stage ER+/HER2- breast cancer. About 15 patients whose blood tests show residual cancer DNA will take capecit…
Matched conditions: ER-POSITIVE HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
BREAST CANCER BREAKTHROUGH? new study lets patients choose chemo-free treatment
Disease control Recruiting nowThis study is for people with a common type of breast cancer (ER-positive, HER2-negative) that has a moderate to high risk of coming back based on tumor size and lymph node involvement, but a low genetic risk score. Instead of chemotherapy after surgery, participants can choose t…
Matched conditions: ER-POSITIVE HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New trial aims to tailor breast cancer therapy using genetic tests
Disease control Recruiting nowThis phase II trial is testing whether using specific genetic tests (Ki67 and Oncotype DX) can help doctors choose the best treatment before surgery for women with a common type of breast cancer (ER-positive, HER2-negative). The study includes 81 postmenopausal women with stage I…
Matched conditions: ER-POSITIVE HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC